Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, filed this Form 6-K for the month of March 2023. The filing, dated March 30, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
The filing text does not provide details on material changes versus prior periods. The content is limited to the procedural inclusion of the March 30, 2023, press release.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in the provided text. The filing references a press release for these details but does not contain the text of that release.
Key Facts for Investor Verification
- Verify the content of the press release dated March 30, 2023, referenced as Exhibit 99.1, as the filing itself contains no operational or financial data.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on March 30, 2023.